Insights

Strategic assets sale Otonomy recently completed the sale of selected assets to Spiral Therapeutics, indicating a potential exit event and openness to partnerships that leverage remaining capabilities or IP in inner ear drug delivery.

Pipeline consolidation Past program results show certain assets (OTIPRIO, OTO-313, OTO-413) faced clinical hurdles or discontinuation. This signals a market where collaboration could reframe or repurpose assets with unmet needs in tinnitus, Ménière’s disease, or hearing loss.

IP strength Otonomy emphasizes a broad patent estate around sustained local drug delivery to the ear, suggesting BD opportunities around licensing or co-development of next-generation delivery platforms or formulations.

Clinical focus With a small team and a history of biotech R&D in otology, Otonomy may seek strategic partnerships to accelerate late-stage or preclinical programs, especially in neurotology indications where external funding and expertise can de-risk development.

Financial posture While revenue is under 1M, the company has substantial funding ($498M) and recent strategic asset disposition, implying readiness to engage in deals that monetize residual expertise, IP, or pipeline potential through collaboration or licensing.

Similar companies to Otonomy, Inc

Otonomy, Inc Tech Stack

Otonomy, Inc uses 8 technology products and services including UserWay, Drupal, WordPress, and more. Explore Otonomy, Inc's tech stack below.

Media & News

Otonomy, Inc's Email Address Formats

Otonomy, Inc uses at least 2 email formats:
Otonomy, Inc Email FormatsExamplePercentage
FLast@otonomy.comJDoe@otonomy.com
88%
First.Last@otonomy.comJohn.Doe@otonomy.com
12%

Frequently Asked Questions

What is Otonomy, Inc's phone number?

Minus sign iconPlus sign icon
You can contact Otonomy, Inc's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Otonomy, Inc's official website and social media links?

Minus sign iconPlus sign icon
Otonomy, Inc's official website is otonomy.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Otonomy, Inc generate?

Minus sign iconPlus sign icon
As of November 2026, Otonomy, Inc's annual revenue is estimated to be <$1M.

What is Otonomy, Inc's SIC code and NAICS code?

Minus sign iconPlus sign icon
Otonomy, Inc's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Otonomy, Inc have currently?

Minus sign iconPlus sign icon
As of November 2026, Otonomy, Inc has approximately 3 employees across 1 continents, including North America. Key team members include Chief Scientific Officer: K. B., Chief Finance Officer: P. C. and President: I. T. Explore Otonomy, Inc's employee directory with LeadIQ.

What industry does Otonomy, Inc belong to?

Minus sign iconPlus sign icon
Otonomy, Inc operates in the Biotechnology Research industry.

What technology does Otonomy, Inc use?

Minus sign iconPlus sign icon
Otonomy, Inc's tech stack includes UserWay, Drupal, WordPress, Shopify, Google Fonts API, Google Cloud, WP Engine and New Relic.

What is Otonomy, Inc's email format?

Minus sign iconPlus sign icon
Otonomy, Inc's email format typically follows the pattern of FLast@otonomy.com. Find more Otonomy, Inc email formats with LeadIQ.

How much funding has Otonomy, Inc raised to date?

Minus sign iconPlus sign icon
As of November 2026, Otonomy, Inc has raised $498M in funding. The last funding round occurred on Apr 07, 2021 for $35M.

When was Otonomy, Inc founded?

Minus sign iconPlus sign icon
Otonomy, Inc was founded in 2008.
Otonomy, Inc logo

Otonomy, Inc

Biotechnology ResearchCalifornia, United States2-10 Employees

Otonomy, Inc. is a biopharmaceutical company focused on developing therapeutics for ear-related diseases and disorders. Its work centers on delivering drugs directly to the ear to achieve sustained exposure from a single local administration, leveraging a broad patent portfolio to pursue treatments for unmet medical needs such as Ménière’s disease, hearing loss, and tinnitus. The company’s activities sit within the biotechnology research sector, specifically neurotology, and involve advancing a pipeline of products aimed at improving outcomes for patients with ear conditions. Based in San Diego, California, Otonomy operates with a small team and has a history of pursuing partnerships and clinical development in alignment with its ear-focused therapeutic strategy.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2008
Employees
2-10

Section iconFunding & Financials

  • $498M

    Otonomy, Inc has raised a total of $498M of funding over 10 rounds. Their latest funding round was raised on Apr 07, 2021 in the amount of $35M as a Post IPO Equity.

  • <$1M

    Otonomy, Inc's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.